DEINOVE to present at upcoming U.S. investors ROTH conference
- The ROTH conference brings together several thousand U.S. investors focused on small and mid-cap growth companies.
- Emmanuel PETIOT will present the Company on Tuesday, March 15th, 2016.
MONTPELLIER, France, March 1, 2016 (GLOBE NEWSWIRE) -- DEINOVE (Alternext Paris: ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals by using Deinococcus bacteria as host strains, announces that Emmanuel PETIOT, Chief Executive Officer, will present at the 28th annual ROTH conference within the "Cleantech and Industrial growth" track, in Dana Point, CA, United States.
He will speak on Tuesday, March 15th, at 5:30 p.m. local time and will also meet one-on-one with investors.
A live webcast of the conference presentation will be available on the Investor Relations section of DEINOVE's website:
http://www.deinove.com/en/investor-room/documentation-center/presentations-shareholders
A replay of the webcast will also be available on this site for 90 days following the live event.
About the ROTH Conference
The 28th annual ROTH Conference, hosted by Roth Capital Partners, is one of the largest of its kind in the U.S. with over 3,000 attendees each year. It will be held on March 13-16, 2016 at The Ritz Carlton in Dana Point, California. The conference will feature company presentations, expert panels and one-on-one meetings.
About DEINOVE
DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria's unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce high value-added products from non-food biomass. The Company's primary markets are 2nd-generation biofuels (DEINOL) and bio-based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally. Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs almost 50 people in its offices and laboratories located in Montpellier, France.
More information at www.deinove.com
Contacts
|
DEINOVE Emmanuel Petiot CEO Tel.: +33 (0)4 48 19 01 28 emmanuel.petiot@deinove.com |
Coralie Martin Communication, Marketing and IR Manager Tel.: +33 (0)4 48 19 01 60 coralie.martin@deinove.com |
|
ALIZE RP, Press Relations Caroline Carmagnol / Wendy Rigal Tel.: +33 (0)1 44 54 36 66 deinove@alizerp.com |
PR DEINOVE ROTH conference http://hugin.info/142979/R/1990663/731435.pdf
HUG#1990663
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
